Targeted Cancer Therapy: Small Molecules and Immunotherapy
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 3419
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer remains the second leading cause of death and morbidity worldwide, with 9.6 million deaths in 2018. Conventional cytotoxic agents have low therapeutic index and frequently display toxicity in cells. The need for innovative chemotypes and the identification of new cancer-relevant targets therefore crucial. In addition to recently developed materials and nanotechnologies, antibody–drug conjugates (ADCs) are still the current vehicles of choice for targeted delivery in Oncology. Over the last couple of years, the use of low-molecular-weight-targeted agents, used as small molecule drug conjugates (SMDCs), has slowly established as a promising alternative to overcome ADCs' limitations.
Exploiting new biomarkers for selective cancer imaging and targeted delivery of therapeutic agents (e.g., cytotoxic agents, small-molecule inhibitors, siRNA, immunomodelators) a pioneering and original means of defying several cancer types.
This Special Issue intentends to publish original and/or review articles covering the state-of-the-art and future viewpoints of targeted therapies in cancer treatment.
Prof. Dr. Marta Coimbra Marques
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- selective targeted therapy
- biomarkers
- antibody–drug conjugates
- small molecule drug conjugates
- immunomodelators
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.